EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Updates on the Biological Heterogeneity of Mantle Cell Lymphoma

Andrew Ip iD, Maciej Kabat iD, Lindsay Fogel iD, Hassan Alkhatatneh iD, Jason Voss, Amolika Gupta, Alexandra Della Pia iD, Lori A Leslie iD, Tatyana Feldman, Maher Albitar, Andre H Goy

Cancers · 19.02.2025 · 17 (4) · 696

DOI: 10.3390/cancers17040696 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 19.02.2025. Verfasst von Andrew Ip und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Advancements in mantle cell lymphoma (MCL) have illuminated the disease’s molecular diversity, leading to a wide variation in the outcomes observed in MCL. Current prognostic risk scores are continuously revised to incorporate new updates in the mechanistic or biologic understanding of MCL. Nevertheless, key high-risk features of MCL associated with rapid disease progression and poor survival, such as TP53 mutations, complex karyotypes, and blastoid or pleomorphic morphologies, remain absent from available prognostic tools. The greater accessibility of genomic technologies, such as next-generation sequencing (NGS), has enabled clinicians to identify specific genetic alterations that serve as prognostic signals and disease monitoring parameters, cultivating accurate risk profiling that is illustrative of MCL heterogeneity. Through an increased understanding of distinct MCL behaviors, novel therapies that mechanistically target disease biology, including Bruton’s tyrosine kinase inhibitors, BCL-2 inhibitors, ROR1 inhibitors, and bispecific T-cell engagers, have broadened the treatment armamentarium for relapsed/refractory MCL cases. These interventions, in addition to chemoimmunotherapy and autologous stem cell transplantation mainstays, confer the individualization of treatment and improved survival outcomes. Further exploration of the considerable biological heterogeneity of MCL can enhance knowledge, management, and the treatment of this rare lymphoma subtype.

Schlagwörter

Stichwörter der Autor:innen

Bruton’s tyrosine kinase inhibitorsNGSheterogeneitymantle cell lymphomanovel therapiesrelapsed/refractory MCLrisk profiling

Autor:innen und Institutionen

  • Department of Oncology, Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA.
  • John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, NJ 07601, USA.
  • Department of Internal Medicine, Hackensack University Medical Center, Hackensack, NJ 07601, USA.
  • Hackensack Meridian School of Medicine, Nutley, NJ 07110, USA.
  • Jefferson Einstein Philadelphia Hospital, Philadelphia, PA 19141, USA.
  • Inova Fairfax Hospital, Falls Church, VA 22042, USA.

ORCID-Profile: Andrew Ip, Maciej Kabat, Lindsay Fogel, Hassan Alkhatatneh, Alexandra Della Pia, Lori A Leslie

Zitieren

APA

Ip, A., Kabat, M., Fogel, L., Alkhatatneh, H., Voss, J., Gupta, A., Della Pia, A., Leslie, L. A., Feldman, T., Albitar, M., & Goy, A. H. (2025). Updates on the Biological Heterogeneity of Mantle Cell Lymphoma. Cancers, 17(4), 696. https://doi.org/10.3390/cancers17040696

Vancouver

Ip A, Kabat M, Fogel L, Alkhatatneh H, Voss J, Gupta A, et al. Updates on the Biological Heterogeneity of Mantle Cell Lymphoma. Cancers. 2025;17(4):696. doi:10.3390/cancers17040696

BibTeX
@article{Ip2025,
  author = {Ip, Andrew and Kabat, Maciej and Fogel, Lindsay and Alkhatatneh, Hassan and Voss, Jason and Gupta, Amolika and Della Pia, Alexandra and Leslie, Lori A and Feldman, Tatyana and Albitar, Maher and Goy, Andre H},
  title = {Updates on the Biological Heterogeneity of Mantle Cell Lymphoma},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {4},
  pages = {696},
  doi = {10.3390/cancers17040696}
}
Kostenlos starten →